214 related articles for article (PubMed ID: 32187357)
1. YWHAE/14-3-3ε expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma.
Xu Y; Fulciniti M; Samur MK; Ho M; Deng S; Liu L; Wen K; Yu T; Chyra Z; Dereibal S; Zhang L; Yao Y; Chakraborty C; Morelli E; Li N; Lopez MA; Perini T; Mu S; An G; Alonso R; Bianchi G; Tai YT; Anderson KC; Qiu L; Munshi NC
Blood; 2020 Jul; 136(4):468-479. PubMed ID: 32187357
[TBL] [Abstract][Full Text] [Related]
2. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
3. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.
Brünnert D; Kraus M; Stühmer T; Kirner S; Heiden R; Goyal P; Driessen C; Bargou RC; Chatterjee M
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1666-1676. PubMed ID: 30954557
[TBL] [Abstract][Full Text] [Related]
4. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
[TBL] [Abstract][Full Text] [Related]
5. Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors.
Besse A; Besse L; Kraus M; Mendez-Lopez M; Bader J; Xin BT; de Bruin G; Maurits E; Overkleeft HS; Driessen C
Cell Chem Biol; 2019 Mar; 26(3):340-351.e3. PubMed ID: 30612952
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors.
Prelowska MK; Mehlich D; Ugurlu MT; Kedzierska H; Cwiek A; Kosnik A; Kaminska K; Marusiak AA; Nowis D
Cancer Lett; 2021 Jun; 507():13-25. PubMed ID: 33713737
[TBL] [Abstract][Full Text] [Related]
7. MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma.
Qiang YW; Ye S; Chen Y; Buros AF; Edmonson R; van Rhee F; Barlogie B; Epstein J; Morgan GJ; Davies FE
Blood; 2016 Dec; 128(25):2919-2930. PubMed ID: 27793878
[TBL] [Abstract][Full Text] [Related]
8. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
Kuhn DJ; Chen Q; Voorhees PM; Strader JS; Shenk KD; Sun CM; Demo SD; Bennett MK; van Leeuwen FW; Chanan-Khan AA; Orlowski RZ
Blood; 2007 Nov; 110(9):3281-90. PubMed ID: 17591945
[TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma.
Xie Y; Liu J; Jiang H; Wang J; Li X; Wang J; Zhu S; Guo J; Li T; Zhong Y; Zhang Q; Liu Z
Oncogene; 2020 Jan; 39(4):922-934. PubMed ID: 31576013
[TBL] [Abstract][Full Text] [Related]
10. RFWD2 induces cellular proliferation and selective proteasome inhibitor resistance by mediating P27 ubiquitination in multiple myeloma.
Gu C; Lu T; Wang W; Shao M; Wei R; Guo M; Li R; Qiao L; Hu Y; Zhan F; Seckinger A; Hose D; Yang Y
Leukemia; 2021 Jun; 35(6):1803-1807. PubMed ID: 32901100
[No Abstract] [Full Text] [Related]
11. Oxidatively modified low-density lipoproteins are potential mediators of proteasome inhibitor resistance in multiple myeloma.
Polusani SR; Cortez V; Esparza J; Nguyen HN; Fan H; Velagaleti GVN; Butler MJ; Kinney MC; Oyajobi BO; Habib SL; Asmis R; Medina EA
Int J Cancer; 2021 Jun; 148(12):3032-3040. PubMed ID: 33521927
[TBL] [Abstract][Full Text] [Related]
12. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Kraus J; Kraus M; Liu N; Besse L; Bader J; Geurink PP; de Bruin G; Kisselev AF; Overkleeft H; Driessen C
Cancer Chemother Pharmacol; 2015 Aug; 76(2):383-96. PubMed ID: 26099967
[TBL] [Abstract][Full Text] [Related]
13. Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells.
Thompson RM; Dytfeld D; Reyes L; Robinson RM; Smith B; Manevich Y; Jakubowiak A; Komarnicki M; Przybylowicz-Chalecka A; Szczepaniak T; Mitra AK; Van Ness BG; Luczak M; Dolloff NG
Oncotarget; 2017 May; 8(22):35863-35876. PubMed ID: 28415782
[TBL] [Abstract][Full Text] [Related]
14. IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma.
Chong PSY; Zhou J; Lim JSL; Hee YT; Chooi JY; Chung TH; Tan ZT; Zeng Q; Waller DD; Sebag M; Chng WJ
Cancer Res; 2019 Sep; 79(18):4679-4688. PubMed ID: 31337650
[TBL] [Abstract][Full Text] [Related]
15. Non-lethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cells.
Skorda A; Sklirou AD; Sakellaropoulos T; Gianniou DD; Kastritis E; Terpos E; Tsitsilonis OE; Florea BI; Overkleeft HS; Dimopoulos MA; Alexopoulos LG; Trougakos IP
J Cell Mol Med; 2019 Dec; 23(12):8010-8018. PubMed ID: 31568628
[TBL] [Abstract][Full Text] [Related]
16. Acute accumulation of PIM2 and NRF2 and recovery of β5 subunit activity mitigate multiple myeloma cell susceptibility to proteasome inhibitors.
Sogabe K; Nakamura S; Higa Y; Miki H; Oda A; Maruhashi T; Sumitani R; Oura M; Takahashi M; Nakamura M; Maeda Y; Hara T; Yamagami H; Fujii S; Kagawa K; Ozaki S; Kurahashi K; Endo I; Aihara KI; Nakaue E; Hiasa M; Teramachi J; Harada T; Abe M
Int J Hematol; 2024 Mar; 119(3):303-315. PubMed ID: 38245883
[TBL] [Abstract][Full Text] [Related]
17. Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells.
Baranowska K; Misund K; Starheim KK; Holien T; Johansson I; Darvekar S; Buene G; Waage A; Bjørkøy G; Sundan A
Oncotarget; 2016 Oct; 7(43):70845-70856. PubMed ID: 27683126
[TBL] [Abstract][Full Text] [Related]
18. Pluronic block copolymers enhance the anti-myeloma activity of proteasome inhibitors.
Hu H; Petrosyan A; Osna NA; Liu T; Olou AA; Alakhova DY; Singh PK; Kabanov AV; Faber EA; Bronich TK
J Control Release; 2019 Jul; 306():149-164. PubMed ID: 31121280
[TBL] [Abstract][Full Text] [Related]
19. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition.
Bianchi G; Oliva L; Cascio P; Pengo N; Fontana F; Cerruti F; Orsi A; Pasqualetto E; Mezghrani A; Calbi V; Palladini G; Giuliani N; Anderson KC; Sitia R; Cenci S
Blood; 2009 Mar; 113(13):3040-9. PubMed ID: 19164601
[TBL] [Abstract][Full Text] [Related]
20. Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors.
Bat-Erdene A; Miki H; Oda A; Nakamura S; Teramachi J; Amachi R; Tenshin H; Hiasa M; Iwasa M; Harada T; Fujii S; Sogabe K; Kagawa K; Yoshida S; Endo I; Aihara K; Abe M
Oncotarget; 2016 Nov; 7(48):79064-79075. PubMed ID: 27738323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
